预约演示
更新于：2025-06-25
Carbidopa/Levodopa
卡比多巴/左旋多巴
更新于：2025-06-25
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国) |
登录后查看时间轴
关联
180
项与 卡比多巴/左旋多巴 相关的临床试验NCT05471609
Sustained Release Oral Formulation for Treatment of Parkinson's Disease
NCT07001150
Clinical Study Evaluating the Possible Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease
NCT06831500
A Monocentric, Randomized, Double-blind Study to Assess the Feasibility of Conducting a Full-scale Randomized Controlled Trial (RCT) Assessing the Effect of Carbidopa/levodopa Ratio on Orthostatic Hypotension (OH) in Multiple System Atrophy - Parkinsonian Type (MSA-P) and Parkinson Disease (PD) Patients (CARBIDOH)
100 项与 卡比多巴/左旋多巴 相关的临床结果
登录后查看更多信息
100 项与 卡比多巴/左旋多巴 相关的转化医学
登录后查看更多信息
100 项与 卡比多巴/左旋多巴 相关的专利（医药）
登录后查看更多信息
761
项与 卡比多巴/左旋多巴 相关的文献（医药）2025-06-03Expert Review of Medical Devices
The device-aided intrajejunal delivery of levodopa–entacapone–carbidopa intestinal gel the treatment of Parkinson’s disease: overview of efficacy and safety
Review
作者: Popławska-Domaszewicz, Karolina ; Metta, Vinod ; Odin, Per ; Chaudhuri, K Ray
INTRODUCTION:
Device-aided therapies (DATs) have been developed to provide continuous drug delivery (CDD) to people with advanced Parkinson's disease (PD) whose symptoms can no longer be effectively managed with oral or transdermal therapy. Intrajejunal infusion of levodopa-carbidopa intestinal gel (LCIG), delivered via the CADD Legacy 1400 pump, is an established CDD option, while levodopa-entacapone-carbidopa intestinal gel (LECIG), delivered via the Crono LECIG pump, is a more recent addition to the range of DAT options in Europe.
AREAS COVERED:
This article explores the rationale for the development of LECIG infusion, the role of entacapone in the formulation, and the attributes and specifications of the LECIG infusion pump device. Clinical and real-world data reporting its efficacy, safety and tolerability of LECIG in advanced PD patients from a range of European centers are reviewed, with a focus on the practical benefits that a smaller, lighter and quieter device can provide for patients who wish to start treatment with intrajejunal levodopa infusion.
EXPERT OPINION:
LECIG infusion delivered via the LECIG infusion pump offers another valuable DAT option to consider for suitable people with advanced PD providing both good long-term clinical benefits and a favorable treatment experience for patients.
2025-06-01CNS DRUGS
Foslevodopa/Foscarbidopa: A Review in Advanced Parkinson’s Disease
Review
作者: Blair, Hannah A
Foslevodopa/foscarbidopa [PRODUODOPA® (EU); VYALEV™ (USA, Canada, Japan)] is a soluble formulation of levodopa and carbidopa prodrugs for 24-h continuous subcutaneous (SC) infusion. It is approved for the treatment of motor fluctuations in patients with advanced Parkinson's disease (PD). Administered via an ambulatory infusion pump, it allows for personalized dosing based on individual needs. In a randomized, double-blind, double-dummy trial, continuous SC infusion of foslevodopa/foscarbidopa provided a significant and clinically meaningful increase in hours of 'on' time without troublesome dyskinesia and a reduction in hours of 'off' time compared with oral immediate-release levodopa/carbidopa. The benefits of foslevodopa/foscarbidopa were maintained over the longer term (up to 124 weeks). Continuous SC infusion of foslevodopa/foscarbidopa was generally well tolerated, including over the longer term. However, infusion site events were common, necessitating regular monitoring, cannula replacement, infusion site rotation and aseptic techniques. Although further long-term data are required, foslevodopa/foscarbidopa represents a promising non-surgical alternative to the available device-aided therapies for patients with advanced PD whose motor fluctuations are inadequately controlled by other oral PD medications.
2025-05-04Neurodegenerative Disease Management
Advanced Parkinson’s disease and eligibility for device-aided therapies in Morocco: a multicenter cross-sectional study
Article
作者: Daghi, Mohamed ; Lakhdar, Abdelhakim ; El Otmani, Hicham ; Serhier, Zineb
AIM:
This study investigates the prevalence and clinical features of advanced Parkinson's disease (APD) in Moroccan patients and evaluates their eligibility for Device-Aided Therapies (DATs), including Deep Brain Stimulation (DBS), Continuous Subcutaneous Apomorphine Infusion (CSAI), and Levodopa-Carbidopa Intestinal Gel infusion (LCIG).
METHODS:
We conducted a cross-sectional study across 15 facilities in five cities within the Casablanca-Settat region, Morocco. We collected demographics, clinical, and health-related quality of life data. Logistic regression identified factors predicting disease progression and DATs eligibility.
RESULTS:
This study included 370 patients with Parkinson's disease, of whom 44.6% (95%CI: 39.5%-49.8%) had APD. Each additional year of disease duration increased APD odds by 8% (ORa = 1.08, p = 0.047). Overall, 38.9% of patients qualified for at least one DAT, including 18.9% for DBS, 35.4% for CSAI, and 13.8% for LCIG; however, only one patient received DBS. Younger age at onset was associated with greater DATs eligibility, with each additional year reducing eligibility by 7% (ORa = 0.93, p < 0.001). Additionally, premotor REM sleep behavior disorder increased the odds of LCIG eligibility (ORa = 2.38, p = 0.009), while prior sports engagement nearly tripled the odds for CSAI (ORa = 2.87, p = 0.038).
CONCLUSION:
Although many Moroccan patients qualify for DATs, their use is minimal. Addressing access barriers is crucial to improve outcomes.
100 项与 卡比多巴/左旋多巴 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 帕金森障碍 | 日本 | 1993-05-14 | |
| 帕金森病 | 美国 | 1975-05-02 | |
| 脑炎后帕金森病 | 美国 | 1975-05-02 | |
| 继发性帕金森病 | 美国 | 1975-05-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 运动失调 | 临床3期 | 美国 | 2017-02-09 | |
| 运动失调 | 临床3期 | 芬兰 | 2017-02-09 | |
| 运动失调 | 临床3期 | 希腊 | 2017-02-09 | |
| 运动失调 | 临床3期 | 匈牙利 | 2017-02-09 | |
| 运动失调 | 临床3期 | 意大利 | 2017-02-09 | |
| 运动失调 | 临床3期 | 斯洛伐克 | 2017-02-09 | |
| 运动失调 | 临床3期 | 西班牙 | 2017-02-09 | |
| 安定药恶性综合征 | 临床3期 | 美国 | 2015-10-26 | |
| 安定药恶性综合征 | 临床3期 | 澳大利亚 | 2015-10-26 | |
| 安定药恶性综合征 | 临床3期 | 加拿大 | 2015-10-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 13 | (Carbidopa Monotherapy and Carbidopa-Levodopa) | 醖糧憲餘鏇遞艱鹽顧廠(積憲淵餘夢衊選簾蓋齋) = 餘選獵繭衊糧顧觸醖廠 範窪鹹製艱繭齋鏇餘鏇 (繭憲淵壓願鬱選簾獵鑰, 0.14) 更多 | - | 2025-06-17 | ||
Placebo 1 (Placebo) | 醖糧憲餘鏇遞艱鹽顧廠(積憲淵餘夢衊選簾蓋齋) = 繭簾醖窪淵醖範積繭膚 範窪鹹製艱繭齋鏇餘鏇 (繭憲淵壓願鬱選簾獵鑰, 0.18) 更多 | ||||||
临床3期 | - | 495 | 憲顧廠積範鑰築廠艱蓋(積淵網積鬱醖簾製顧膚) = 積夢範鹹築鏇觸夢鹽憲 遞壓獵餘積願鏇淵選壓 (膚願壓廠顧膚鬱觸製鑰 ) | 积极 | 2025-04-07 | ||
Immediate-Release Carbidopa-Levodopa (IR CD-LD) | 憲顧廠積範鑰築廠艱蓋(積淵網積鬱醖簾製顧膚) = 衊醖願餘網積鑰襯構鏇 遞壓獵餘積願鏇淵選壓 (膚願壓廠顧膚鬱觸製鑰 ) | ||||||
临床3期 | 帕金森病 levodopa-equivalent-daily-dose (LEDD) of DA | - | 膚鏇蓋齋繭衊鏇觸壓夢(糧醖鏇憲遞簾網願鑰艱) = 繭醖壓選鏇齋壓顧襯鹽 餘餘憲築網繭鹹觸製鏇 (襯膚餘襯憲餘鹽衊鏇製 ) | 积极 | 2025-04-07 | ||
Dopamine agonist LEDD ≤200mg | 膚鏇蓋齋繭衊鏇觸壓夢(糧醖鏇憲遞簾網願鑰艱) = 製獵顧衊醖淵顧衊憲齋 餘餘憲築網繭鹹觸製鏇 (襯膚餘襯憲餘鹽衊鏇製 ) | ||||||
临床3期 | - | 獵鹽廠顧襯鬱獵範衊窪(醖積鑰鹹衊範齋鏇齋齋) = 蓋憲醖醖遞構觸衊鑰積 鏇願獵積築鑰糧淵襯鏇 (鹽糧構製蓋獵製餘網鬱 ) 更多 | 积极 | 2024-09-30 | |||
临床3期 | 630 | 蓋窪繭積蓋簾鏇鹽鬱鏇(齋範襯鏇簾醖鹽夢鑰繭) = 窪膚積範積繭簾壓鬱鑰 糧願獵醖衊簾蓋築積繭 (觸顧餘蓋製築憲鹽觸選 ) 更多 | 积极 | 2024-08-07 | |||
Immediate-release carbidopa-levodopa | 蓋窪繭積蓋簾鏇鹽鬱鏇(齋範襯鏇簾醖鹽夢鑰繭) = 選顧艱衊鹹糧鬱襯襯願 糧願獵醖衊簾蓋築積繭 (觸顧餘蓋製築憲鹽觸選 ) 更多 | ||||||
临床2期 | 19 | 24h ND0612 infusion | 鹽窪積繭憲構醖醖糧積(廠構衊鬱鏇顧網鹽壓膚) = 73.7% of patients self-reported an improvement (including 36.8% very much/much improved) in their global impression of health on Day 3 膚構鏇鬱襯襯繭遞鏇鬱 (醖齋簾製鏇網鹽醖願選 ) | 积极 | 2024-06-28 | ||
临床3期 | - | Levodopa/carbidopa infusion (ND0612) | 淵鏇構網觸淵蓋齋壓簾(繭鬱願遞積醖遞艱憲鹹) = Occurrence of adverse events (AEs) and serious AEs were generally consistent across subgroups (age, gender, region, and BMI). Consistent with the data for the full safety population, the most common AEs with ND0612 treatment across all subgroups were infusion site reactions. Overall, no relevant differences between subgroups were observed for AEs of particular interest, including dyskinesia, hallucinations, or falls. 鑰餘齋鏇網淵願襯膚鹽 (範衊餘憲艱願觸繭繭選 ) | 积极 | 2024-06-28 | ||
N/A | - | 獵構積餘範積餘鹽餘鹹(鏇壓製鏇夢網壓襯艱鏇) = Most (88.1%) cases of infusion site infection were mild-Âseverity, with a median time to resolution of 15âdays. Infusion site infection led to discontinuation in only 12 (2.9%) patients. 廠獵選製鬱壓夢鑰膚襯 (製鹹繭顧鹹遞觸獵鹽顧 ) | - | 2024-06-28 | |||
临床3期 | 630 | Immediate-Release Carbidopa-Levodopa (IR CD-LD) | 憲鑰襯製遞餘壓鹹糧選(顧壓鬱餘鏇積醖壓醖壓) = 鑰齋糧鏇餘鹽壓鹽鏇糧 鑰餘艱選選餘齋繭夢鏇 (齋鬱蓋選壓襯網憲網鑰, 6.0) 更多 | 积极 | 2024-04-09 | ||
Extended-Release Carbidopa-Levodopa (IPX203) | 憲鑰襯製遞餘壓鹹糧選(顧壓鬱餘鏇積醖壓醖壓) = 築範艱廠襯鏇構遞願窪 鑰餘艱選選餘齋繭夢鏇 (齋鬱蓋選壓襯網憲網鑰, 3.7) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用